Answers are grounded in this paper and cite their sources.
A double-stranded RNA of fungal origin (BRL 5907) was given intranasally to volunteers. Apart from mild local irritancy of the higher dosage, the compound was well tolerated. A double-blind placebo-controlled trial of a three-day course (5 mg per day) of BRL 5907 against challenge with rhinovirus type 4 showed that treatment was associated with a delay in onset of symptoms and a reduction in shedding of virus, but the differences were not statistically significant. Low titers of interferon were found in nasal washings.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: